Metformin as Adjuvant Therapy in Obese Knee Osteoarthritis Patients

• Status: Completed
• Trial end date: 2022-04-15
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the possible efficacy and safety of addition of metformin to celecoxib in patients with knee osteoarthritis.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Patients have symptomatic and radiological evidence of OA in one or both knee joints.

Age ≥ 45 years. Both obese male and female will be included (BMI ≥ 30 kg/m²).

Exclusion Criteria:

• Patients with inflammatory rheumatic diseases, crystal deposition arthritis or infection-induced OA.

Patient with hypertension or diabetes mellitus. Patient with hepatic or renal impairment. Patients who have active peptic ulcer. Patients with positive malignancy. Steroid injection into the affected knee joint within 3 months of recruitment for the study.

Pregnant or lactating female patients.